NewAmsterdam Pharma Company (NAMS) AI Stock Analysis

• Market Cap: $2.49B
• Dividend Yield: N/A
• Average Volume (3M): 928.85K
• Price to Earnings (P/E): ―
• Beta (1Y): 1.88
• Revenue Growth: N/A
• EPS Growth: N/A
• Country: US
• Employees: 68
• Sector: Healthcare
• Sector Strength: 40
• Industry: Biotechnology
• EPS (TTM): -0.34
• Shares Outstanding: 112,270,676
• 10 Day Avg. Volume: 799,040
• 30 Day Avg. Volume: 928,853
• PEG Ratio: -0.52
• Price to Book (P/B): 3.16
• Price to Sales (P/S): 0.00
• P/FCF Ratio: -17.36
• Enterprise Value/Market Cap: 0.65
• Enterprise Value/Revenue: 12.01
• Enterprise Value/Gross Profit: 34.19
• Enterprise Value/Ebitda: -1.85
• 1Y Price Target: $41.67
• Price Target Upside: 87.70% Upside
• Rating Consensus: Strong Buy
• Number of Analyst Covering: 11

• Rating: 65 Neutral
• Price Target: $23.50 ▲(5.86%Upside)

NewAmsterdam Pharma's stock is bolstered by recent positive corporate events and strong technical indicators. However, its financial performance and valuation are hindered by operational losses and a negative P/E ratio, typical of the biotech industry. The company's strong revenue growth and low leverage provide stability, but achieving profitability remains crucial for long-term success.

Positive Factors

Commercial Strategy

Important updates on the PREVAIL MACE endpoint trial design, obi commercial strategy, and pipeline expansion increase conviction that NAMS is strategically executing well.

Market Opportunity

There is a substantial commercial opportunity afforded by the broad, accelerating physician preference for the comprehensive LDL+ profile of obi.

R&D Differentiation

NewAmsterdam hosted a comprehensive R&D day event that reinforced obicetrapib's differentiated 'LDL+' clinical profile, indicating potential patient benefits beyond lowering LDL-C.

Negative Factors

Investor Perception

NewAmsterdam's news of statistically significant reductions in plasma p-tau217 represents a potential paradigm-shifting update that is currently underappreciated by investors.

Market Competition

MRK's positive Ph. 3 data helps validate the oral PCSK9 inhibitor space and signals new competition, but also potentially future market expansion growth, in the CVRR landscape.

NewAmsterdam Pharma Company Business Overview & Revenue Model

Company Description

NewAmsterdam Pharma Company (NAMS) is a clinical-stage biopharmaceutical company focused on the research and development of transformative therapies to address cardiovascular diseases. The company operates within the biopharmaceutical sector, leveraging advanced scientific research to create novel treatments. Its core products include investigational therapies aimed at managing and preventing cardiovascular conditions, with a primary focus on dyslipidemia and other metabolic disorders.

How the Company Makes Money

NAMS primarily makes money through the development and commercialization of its proprietary drug candidates. The company's revenue model is centered around successful clinical trials that lead to regulatory approval, allowing it to either license its therapies to larger pharmaceutical companies or directly market them. Key revenue streams include milestone payments from licensing agreements, potential royalty payments from commercialized products, and partnerships with other pharmaceutical companies for co-development and co-marketing efforts. These partnerships provide significant financial support and shared resources, contributing to the company's earnings as it advances its product pipeline.

NewAmsterdam Pharma Company Financial Statement Overview

Summary

The company shows typical characteristics of a biotech firm with high R&D expenses leading to operational losses. Despite strong revenue growth, profitability is a challenge. The balance sheet is robust with low leverage, providing stability, but cash flows are negative due to cash burn issues.

Income Statement

The company's revenue has shown significant volatility with periods of growth and decline. The gross profit margin is 100% due to no cost of goods sold, but the net profit margin is low due to high operating expenses. EBIT and EBITDA margins are negative, indicating operational challenges. Revenue growth from 2023 to 2024 is strong, but the company has not achieved profitability.

Balance Sheet

The company maintains a strong equity position with an equity ratio of 87.6%, indicating low leverage. Debt-to-equity is minimal at 0.06, suggesting low financial risk. However, the company has reported consecutive net losses, impacting return on equity, which remains negative.

Cash Flow

Operating cash flow is consistently negative, highlighting cash burn issues typical in the biotechnology industry. Free cash flow growth is negative, indicating increased outflows. However, ample financing cash flow suggests the company is able to raise capital successfully, mitigating immediate liquidity concerns.

Breakdown	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	45.56M	12.76M	95.91M	0.00	0.00
Gross Profit	45.56M	12.76M	95.91M	0.00	0.00
EBITDA	-241.49M	-176.86M	-3.31M	-30.73M	-5.43M
Net Income	-241.60M	-176.94M	-21.14M	-36.71M	-5.75M
Balance Sheet
Total Assets	864.62M	347.10M	531.58M	59.78M	9.23M
Cash, Cash Equivalents and Short-Term Investments	834.19M	340.45M	438.52M	53.09M	7.86M
Total Debt	448.00K	60.00K	118.00K	164.00K	11.65M
Total Liabilities	107.12M	58.70M	47.06M	9.99M	12.81M
Stockholders Equity	757.50M	288.39M	484.52M	49.79M	-3.58M
Cash Flow
Free Cash Flow	-159.24M	-141.24M	7.96M	-25.18M	-5.98M
Operating Cash Flow	-158.56M	-141.22M	7.97M	-25.16M	-5.97M
Investing Cash Flow	-62.85M	-24.00K	715.00K	-20.00K	-13.00K
Financing Cash Flow	659.51M	8.91M	375.18M	68.99M	11.32M

NewAmsterdam Pharma Company Technical Analysis

• Technical Analysis Sentiment: Positive
• Last Price: 22.20
• 50DMA: Positive
• 100DMA: Positive
• 200DMA: Positive
• MACD: Negative
• RSI: Neutral
• STOCH: Negative

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For NAMS, the sentiment is Positive. The current price of 22.2 is above the 20-day moving average (MA) of 20.13, above the 50-day MA of 19.44, and above the 200-day MA of 20.58, indicating a bullish trend. The MACD of 0.85 indicates Negative momentum. The RSI at 65.29 is Neutral, neither overbought nor oversold. The STOCH value of 81.80 is Negative, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for NAMS.

NewAmsterdam Pharma Company Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
HRMY	80 Outperform	$2.02B	13.42	24.71%	―	20.62%	14.08%
NAMS	65 Neutral	$2.49B	―	-31.51%	―	―	―
RXRX	61 Neutral	$2.52B	―	-86.10%	―	29.32%	-11.00%
ARQT	54 Neutral	$1.75B	―	-70.58%	―	100.03%	64.22%
Sector *	52 Neutral	$7.37B	-0.04	-63.81%	2.59%	16.40%	<0.01%
DNLI	45 Neutral	$2.03B	―	-35.21%	―	-100.00%	-144.79%
MTSR	40 Underperform	$4.49B	―		―	―	―

NewAmsterdam Pharma Company Corporate Events

NewAmsterdam Pharma Updates Employment Agreement with Executive

On July 11, 2025, NewAmsterdam Pharma B.V. updated its Employment Agreement with Dr. John Kastelein, effective July 1, 2025. This agreement outlines severance and benefits for Dr. Kastelein in cases of employment termination without cause or due to a change in control, impacting his stock options and equity awards.

The most recent analyst rating on (NAMS) stock is a Buy with a $48.00 price target. To see the full list of analyst forecasts on NewAmsterdam Pharma Company stock, see the NAMS Stock Forecast page.

NewAmsterdam Pharma Schedules R&D Day for June 2025

NewAmsterdam Pharma Company announced a Research & Development Day event scheduled for June 11, 2025, in New York City, aimed at analysts and investors. The event will be webcast live, with a replay available for 30 days. The company has been active in clinical trials, with significant developments in its BROOKLYN, BROADWAY, and TANDEM Phase 3 studies, and has secured funding to support a potential U.S. commercial launch. The company’s product candidate, Obicetrapib, shows promise in addressing cardiometabolic diseases, and there are ongoing efforts to explore its therapeutic potential in Alzheimer’s disease and multi-infarct dementia.

The most recent analyst rating on (NAMS) stock is a Buy with a $48.00 price target. To see the full list of analyst forecasts on NewAmsterdam Pharma Company stock, see the NAMS Stock Forecast page.

NewAmsterdam Pharma Announces Positive Phase 3 Trial Results

On June 9, 2025, NewAmsterdam Pharma announced positive topline data from their Phase 3 BROADWAY clinical trial, which evaluated the effects of obicetrapib on Alzheimer’s Disease biomarkers. The study showed statistically significant reductions in the primary outcome measure of p-tau217 in both the full study population and ApoE4 carriers, suggesting a potential preventive strategy for Alzheimer’s Disease. These findings highlight the potential of CETP inhibition in mitigating Alzheimer’s risk and further differentiate obicetrapib as a uniquely effective therapy addressing multiple health concerns, including cardiovascular and neurodegenerative diseases.

The most recent analyst rating on (NAMS) stock is a Buy with a $48.00 price target. To see the full list of analyst forecasts on NewAmsterdam Pharma Company stock, see the NAMS Stock Forecast page.

NewAmsterdam Pharma Approves Key Proposals at AGM

On June 4, 2025, NewAmsterdam Pharma Company N.V. held its annual general meeting where 74.45% of eligible shares voted. Shareholders approved several proposals, including the adoption of the 2024 annual accounts, discharge of directors’ liabilities, appointment of Deloitte as auditor, and various board appointments. The company also decided to hold annual Say-on-Pay votes until 2031.

The most recent analyst rating on (NAMS) stock is a Buy with a $40.00 price target. To see the full list of analyst forecasts on NewAmsterdam Pharma Company stock, see the NAMS Stock Forecast page.

NewAmsterdam Pharma Presents Promising Phase 3 Trial Data

On May 7, 2025, NewAmsterdam Pharma announced additional data from its BROADWAY and TANDEM Phase 3 clinical trials, presented at the European Atherosclerosis Society Congress and published in leading medical journals. The data demonstrated significant reductions in LDL-C levels and improvements in cardiovascular biomarkers with the use of obicetrapib, both as monotherapy and in combination with ezetimibe, highlighting its potential as a foundational therapy in CVD management. The trials showed a 45% reduction in lipoprotein(a) and a 21% reduction in major adverse cardiovascular events, reinforcing obicetrapib’s promise as an effective oral treatment for CVD.